<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784366</url>
  </required_header>
  <id_info>
    <org_study_id>15302</org_study_id>
    <nct_id>NCT02784366</nct_id>
  </id_info>
  <brief_title>GI Complications in Cancer Immunotherapy Patients</brief_title>
  <official_title>GI Complications in Cancer Immunotherapy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish a prospective observational cohort of cancer
      immunotherapy patients with GI side effects in order to identify biomarkers that predict GI
      complications due to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective

        -  To create a data and bio-specimen repository to enhance both safety and efficacy of
           immunotherapy

      Secondary objective

        -  Identify biomarkers that may predict GI toxicity in cancer patients undergoing
           immunotherapy

        -  Define the clinical course of intestinal inflammation and identify genetic factors of
           therapeutic response to GI medications

        -  Analyze genotype-phenotype correlations in GI side effects in patients undergoing cancer
           immunotherapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>GI disease activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate GI disease activity associated with cancer immunotherapy through a series of standardized questionnaires that measure severity of GI symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biospecimen collection</measure>
    <time_frame>12 weeks</time_frame>
    <description>To collect stool, blood, and colon biopsies and have the ability to identify predictive biomarkers in patients that develop colitis as a result of cancer immunotherapy.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Cancer immunotherapy patients - no GI side effect</arm_group_label>
    <description>Cancer immunotherapy patients who do not develop GI side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer immunotherapy patients - develop GI side effects</arm_group_label>
    <description>Cancer immunotherapy patients who develop GI side effects</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and stool samples will be collected.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of cancer who have undergone or will be undergoing immunotherapy
        will be eligible for recruitment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of cancer

          -  Currently undergoing or have undergone immunotherapy

        Exclusion Criteria:

          -  History of a total colectomy

          -  History of inflammatory bowel disease (either ulcerative colitis or Crohn's disease)

          -  History of colitis on chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashwin Ananthakrishnan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ryan J Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Andrews, BS</last_name>
    <phone>617-724-2090</phone>
    <email>eaandrews@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keri Sullivan, BS</last_name>
    <phone>617-724-5955</phone>
    <email>ksullivan79@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Andrews, BS</last_name>
      <phone>617-724-2090</phone>
      <email>eaandrews@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Keri Sullivan, BS</last_name>
      <phone>617-724-5955</phone>
      <email>ksullivan79@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ashwin Ananthakrishnan, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Michael Dougan</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>Cancer immunotherapy</keyword>
  <keyword>Ipilimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

